Osimertinib, an EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I
Floc'h, Nicolas, Lim, Sangbin, Bickerton, Sue, Ahmed, Afshan, Orme, Jonathan, Urosevic, Jelena, Martin, Matthew J., Cross, Darren AE, Cho, Byoung Chul, Smith, Paul DJournal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-20-0103
Date:
September, 2020
File:
PDF, 1.05 MB
2020
File converter
More search results
More benefits 
